Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Free Cash Flow: 2012-2025

Historic Free Cash Flow for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -$69.7 million.

  • Ptc Therapeutics' Free Cash Flow rose 10.02% to -$69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.2 million, marking a year-over-year increase of 478.59%. This contributed to the annual value of -$114.2 million for FY2024, which is 38.89% up from last year.
  • Ptc Therapeutics' Free Cash Flow amounted to -$69.7 million in Q3 2025, which was down 16.93% from -$59.6 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Free Cash Flow peaked at $868.4 million during Q1 2025, and registered a low of -$174.6 million during Q4 2022.
  • Moreover, its 3-year median value for Free Cash Flow was -$39.8 million (2023), whereas its average is $39.8 million.
  • In the last 5 years, Ptc Therapeutics' Free Cash Flow crashed by 344.25% in 2021 and then soared by 1,319.55% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Free Cash Flow stood at -$77.6 million in 2021, then plummeted by 125.08% to -$174.6 million in 2022, then skyrocketed by 39.37% to -$105.9 million in 2023, then spiked by 68.10% to -$33.8 million in 2024, then rose by 10.02% to -$69.7 million in 2025.
  • Its Free Cash Flow stands at -$69.7 million for Q3 2025, versus -$59.6 million for Q2 2025 and $868.4 million for Q1 2025.